Antibiotic Resistance
Methodology & AI Transparency ⓘ
Antibiotic Resistance Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are antibiotics? Antibiotics are medicines that treat bacterial infections in humans and animals.
- 2 Real-world patient consensus: Diagnostic registry B02.5: Antibiotic Resistance is managed within Infections & Antivirals.
- 3 Typical cash cost range: Workup highlights for Antibiotic Resistance (B02.5): antimicrobial stewardship (narrow-spectrum in Antibiotic Resistance (B02.5: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Objective lab/clinical target for Antibiotic Resistance: Complete Blood Count in Antibiotic Resistance (B02.5: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (B02.5)) and C-Reactive Protein / in Antibiotic Resistance (B02.5: Procalcitonin).
Ask our AI Specialists anything about Antibiotic Resistance
What Is Antibiotic Resistance?
What are antibiotics? Antibiotics are medicines that treat bacterial infections in humans and animals. They work by killing the bacteria or making it hard for the bacteria to grow and multiply. When used properly, antibiotics can save lives. But there is a growing problem of antibiotic resistance. What is antibiotic resistance? Antibiotic resistance happens when bacteria change and can resist the effects of an antibiotic. The bacteria are not killed, and they continue to grow. The infections these bacteria cause are called resistant infections. Resistant infections can be difficult, and sometimes impossible, to treat. In some cases, they can even be deadly.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in infections & antivirals, Antibiotic Resistance (B02.5) involves tissue neutrophil/lymphocyte recruitment [Antibiotic Resistance B02.5]. Cross-referenced with NIH MeSH (Drug Resistance, Bacterial, Drug Resistance, Microbial), progression correlates with shifts in Complete Blood Count in Antibiotic Resistance (B02.5: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (B02.5)).
Common Symptoms & Clinical Signs
- • A long hospital stay
- • Follow-up visits with health care providers
- • Presentation of Antibiotic Resistance (B02.5): sore throat, productive in Antibiotic Resistance (B02.5: cough, sinus/ear pain,)
- • Secondary Antibiotic Resistance clinical sign: painful vesicular rash in Antibiotic Resistance (B02.5: in a dermatomal)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Antibiotic Resistance Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B02.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Antibiotic Resistance (B02.5: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B02.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Antibiotic Resistance (B02.5: Procalcitonin) | Resolution to baseline (B02.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Antibiotic Resistance (B02.5: Culture & Sensitivity) | Pathogen clearance / negative test (B02.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Antibiotic Resistance
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) Sheffield Triple Antibiotic • RxCUI 204602-B11527162 | Aminoglycoside Antibacterial | 77% | $0.0856 | $ 14.66 /mo |
| Atovaquone and Proguanil Hydrochloride Pediatric Atovaquone and Proguanil Hydrochloride Pediatric Generic • RxCUI 864675 | Antimalarial | 82% | $0.8880 | $ 44.47 /mo |
| First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) First Aid Antibiotic and Pain Relief • RxCUI 1359360 | Aminoglycoside Antibacterial | 85% | $5.3182 | $ 391.41 /mo |
| Tetracyte First Aid and Antibiotic Topical (Tetracycline Hydrochloride) Tetracyte First Aid and Antibiotic Topical • RxCUI 1542813-B71262011 | Tetracycline-class Antimicrobial | 87% | $0.5820 | $ 50.41 /mo |
| Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate) Antibiotic • RxCUI 308512 | Polymyxin-class Antibacterial | 87% | $0.0637 | $ 13.09 /mo |
| Triple Antibiotic (Bacitracin Zinc, Neomycin Sulfate, Polymyxin B Sulfate) Triple Antibiotic • RxCUI 204602 | Aminoglycoside Antibacterial | 90% | $0.0637 | $ 13.09 /mo |
| Tobramycin Kitabis Pak, Tobi • RxCUI 313415 | Aminoglycoside Antibacterial | 83% | $1.0548 | $ 8.05 /mo |
| First Aid Antibiotic (Bacitracin) First Aid Antibiotic • RxCUI 1648110-B42507536 | Aminoglycoside Antibacterial | 75% | $0.0637 | $ 13.09 /mo |
| Everlit Care Triple Antibiotic (Bacitracin Zinc, Neomycin Sulfate, Polymyxin B Sulfate) Everlit Care Triple Antibiotic • RxCUI 204602-B43473012 | Aminoglycoside Antibacterial | 92% | $0.0637 | $ 13.09 /mo |
| Tobi (Tobramycin) Tobi • RxCUI 348719-B49502345 | Aminoglycoside Antibacterial | 83% | $1.0769 | $ 193.25 /mo |
| Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine Hydrochloride) Antibiotic and Pain Relief • RxCUI 1359360-B69842754 | Aminoglycoside Antibacterial | 86% | $5.3182 | $ 391.41 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Antibiotic Resistance)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated: What a 377-Participant Study Found Aeruginosa have heterogeneous microbiota and inflammatory profiles, influencing antibiotic treatment responses in bronchiectasis. American journal of respiratory and critical care medicine • 2025-08-15 • Phase III Randomized Trial | N = 377 | 93/100 | PMID 40664229 ↗ |
| New Insights on Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults: What a 1,000-Participant Study Found Both vaccines had an acceptably low reactogenicity profile, and no new safety concerns were found. Vaccine • 2024-03-07 • Phase III Randomized Trial | N = 1,000 | 90/100 | PMID 38365482 ↗ |
| New Insights on Phase 3 study evaluating the safety and real-world benefits of oteseconazole in: What a 219-Participant Study Found In participants with recurrent vulvovaginal candidiasis, oteseconazole was safe and efficacious in the treatment and prevention of recurrent acute vulvovaginal candidiasis episodes and was noninferior to vulvovaginal... American journal of obstetrics and gynecology • 2022-12-15 • Phase III Randomized Trial | N = 219 | 88/100 | PMID 35863457 ↗ |
| Can This Approach Help? Inside the Latest Research on Gut microbial dynamics and antibiotic resistance during rifaximin therapy in RFX treatment reduced microbial richness and decreased the abundance of taxa typically enriched in advanced cirrhosis (e.g., Escherichia , Streptococcus , Veillonella ). Frontiers in cellular and infection microbiology • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42871147 ↗ |
| Can This Approach Help? Inside the Latest Research on Effectiveness and safety of oral vancomycin versus placebo in the prevention of Ethical approval has been obtained from the Ethic Committee for Research with medicinal products of the University Hospital '12 de Octubre' (AC069/18) and from the Spanish Medicines and Healthcare Product Regulatory Agency... BMJ open • 2023-09-13 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37709311 ↗ |
Antibiotic Resistance Patient Community & “People Like Me” Threads
Filter Antibiotic Resistance community threads and patient logs by age, biological sex, dosage, and treatment duration.